NCT04159818View on ClinicalTrials.gov

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 21, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Nivolumab

240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards

DRUG

Cisplatin

40mg/m2, weekly for two weeks

DRUG

Low dose doxorubicin

15mg flat dose, weekly for 8 weeks

Trial Locations (1)

1066 CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT04159818 - Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | Biotech Hunter | Biotech Hunter